HIF2A mutation lead to pseudohypoxic change and tumor formation. (A) Immunoprecipitation assay measuring HIF-2α ubiquitination, showing decreased protein ubiquitination in mutant protein. (B) CHX assay measuring HIF-2α stability, showing elongated protein half-life. (C) Immunohistochemistry staining of HIF-2α in tumor specimens, showing increased HIF-2α protein in tumors. (D) Quantitative polymerase chain reaction assay showing increased hypoxia-related gene expression in tumor specimen. (E) Chromatin immunoprecipitation assay showing intact DNA-binding efficiency of mutant HIF-2α.